CERVOMED INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.74 USD | +2.49% |
|
+5.60% | +162.12% |
| May. 29 | JonesTrading Starts CervoMed With Buy Rating, $70 Price Target | MT |
| May. 20 | CervoMed Names William Elder CFO | MT |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 43.3 | 159 | - | - |
| Enterprise Value (EV) 1 | 43.3 | 113.7 | 46.07 | 95.47 |
| P/E ratio | -9.3 x | -12.1 x | -8.9 x | -6.63 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 6.06 x | 18 x | 27.3 x | - |
| EV / Revenue | 6.06 x | 12.9 x | 7.9 x | - |
| EV / EBITDA | -5.54 x | -7.73 x | -1.25 x | -1.77 x |
| EV / FCF | - | -8.74 x | -1.55 x | -2.22 x |
| FCF Yield | - | -11.4% | -64.4% | -45% |
| Price to Book | - | 3.91 x | 2.26 x | 3.95 x |
| Nbr of stocks (in thousands) | 5,675 | 8,254 | - | - |
| Reference price 2 | 7.630 | 19.26 | 19.26 | 19.26 |
| Announcement Date | 3/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 7.145 | 8.833 | 5.833 | - |
| EBITDA 1 | - | -7.813 | -14.7 | -36.9 | -54 |
| EBIT 1 | - | -7.813 | -12.9 | -26.77 | -38.8 |
| Operating Margin | - | -109.35% | -146.04% | -458.86% | - |
| Earnings before Tax (EBT) 1 | - | -2.172 | -12.25 | -26.5 | -38.53 |
| Net income 1 | -5.803 | -2.172 | -12.25 | -26.5 | -38.53 |
| Net margin | - | -30.4% | -138.68% | -454.29% | - |
| EPS 2 | -1.290 | -0.8200 | -1.587 | -2.163 | -2.907 |
| Free Cash Flow 1 | - | - | -13 | -29.65 | -42.95 |
| FCF margin | - | - | -147.17% | -508.29% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 7/13/23 | 3/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1.526 | 2.491 | 2.347 | 2.1 | 2.1 | 2.1 |
| EBITDA 1 | - | -2.48 | -2.595 | -3.4 | -4.4 | -4.9 |
| EBIT 1 | -2.675 | -2.48 | -2.595 | -2.9 | -3.45 | -3.95 |
| Operating Margin | -175.25% | -99.59% | -110.55% | -138.1% | -164.29% | -188.1% |
| Earnings before Tax (EBT) 1 | 2.15 | -2.362 | -2.514 | -2.7 | -3.3 | -3.75 |
| Net income 1 | 2.15 | -2.362 | -2.514 | -2.7 | -3.3 | -3.75 |
| Net margin | 140.87% | -94.85% | -107.12% | -128.57% | -157.14% | -178.57% |
| EPS 2 | 0.6500 | -0.9500 | -0.4100 | -0.3367 | -0.4133 | -0.4600 |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 11/13/23 | 3/29/24 | 5/14/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | - | 45.3 | 113 | 63.5 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -13 | -29.7 | -43 |
| ROE (net income / shareholders' equity) | - | - | -56.4% | -46.9% | -60.1% |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share 2 | - | - | 4.920 | 8.530 | 4.870 |
| Cash Flow per Share 2 | - | - | -1.680 | -2.470 | -3.530 |
| Capex 1 | - | - | 1 | 2 | 2 |
| Capex / Sales | - | - | 11.32% | 34.29% | - |
| Announcement Date | 7/13/23 | 3/29/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
19.26
USD
Average target price
55
USD
Spread / Average Target
+185.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +162.12% | 159M | |
| +19.10% | 125B | |
| +14.15% | 108B | |
| -4.92% | 24.57B | |
| +3.23% | 22.82B | |
| -10.44% | 18.19B | |
| -41.74% | 16.54B | |
| -13.28% | 16.5B | |
| +2.16% | 13.39B | |
| +28.54% | 11.1B |
- Stock Market
- Equities
- CRVO Stock
- Financials CervoMed Inc.
